Details of the OSE Immunotherapeutics SITC presentation:
- SITC (
Society for Immunotherapy of Cancer ) Annual Meeting,November 10-14, 2020 .
E-poster audio presentation: “CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and synergizing with tumor-targeted antibodies”
Abstract: #212
Presentation Time:Thursday, Nov. 12 , from4:50-5:20 p.m. EST andSaturday, Nov. 14 , from1-1:30 p.m. EST
Posters will be on display from8 a.m. onMonday, Nov. 9 , until the SITC virtual poster hall closes onDecember 31, 2020
Presentation of novel “Don’t Eat Me” receptor CLEC-1, identified in collaboration with DrElise Chiffoleau and the team ofNantes University Hospital , as a novel myeloid immune checkpoint target for cancer immunotherapy. Similar to the SIRPα/CD47 pathway, CLEC1/CLEC1-Ligand pathway inhibits the phagocytosis of macrophages and antigen-presentation by dendritic cells. CLEC-1 ligand differentiates from CD47 as expressed by tumor cells in stress conditions, in particular when combined with cytotoxic and immunogenic chemotherapy. The CLEC-1 monoclonal antibody antagonists developed by OSE release this inhibition and act in synergy with the commercialized antibodies targeting tumor antigens.
Details of additional presentations at immuno-oncology summits:
- Macrophage-directed Therapies Summit,
October 27-29, 2020
Talk on “Don’t Eat me signal Targets as novel innate immune checkpoint inhibitors: the validated SIRPa and novel CLEC-1 targets”
- CD47/SIRPα Summit,
November 4-5, 2020
Plenary lecture: “Fundamental Biology Behind Alternative SIRP Homologs & an Overview of OSE Immunotherapeutics’ Approach”
Presentation of R&D studies and results focused on the interest of “Don’t Eat Me” receptor blockade as a new emergent pathway of interest in immuno-oncology. Translational and preclinical study data conducted in rodent in vivo and human ex vivo models have characterized the efficacy and mechanism of action of BI 765063, formerly OSE-172, the first selective antibody antagonist of SIRPα-mediated “Don’t Eat Me” signals. OSE’s R&D team has identified a complimentary SIRPα-mediated “Don’t Find Me” mechanism of action which reverses a major mechanism of resistance and escape to immunotherapy called “T-cell exclusion.”
ABOUT
Vaccine platform
- Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive results for Step-1 of the Phase 3 trial (
Atalante 1) in Non-Small CellLung Cancer post checkpoint inhibitor failure.
In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR) in monotherapy and in combination with checkpoint inhibitor Opdivo®. - CoVepiT: a prophylactic vaccine against COVID-19, developed using SARS-CoV-2 optimized neo-epitopes. Positive preclinical and human ex vivo results in
August 2020 , clinical trial expected to start Q1 2021.
Immuno-oncology platform
- BI 765063 (OSE-172, anti-SIRPα mAb): developed in partnership with
Boehringer Ingelheim ; myeloid checkpoint inhibitor in Phase 1 in advanced solid tumors. - CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the “Don’t Eat Me” signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.
- BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.
Auto-immunity and inflammation platform
- FR104 (anti-CD28 monoclonal antibody): positive Phase 1 results; Phase 2-ready asset in autoimmune diseases or in transplantation.
- OSE-127 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with
Servier ; positive Phase 1 results; two independent Phase 2 planned in ulcerative colitis (OSE sponsor) and in Sjögren’s syndrome (Servier sponsor) to start in Q4 2020. - OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.
Due to the COVID-19 crisis, accrual of new patients in the clinical trial TEDOPaM is temporarily suspended and initiation timelines for both Phase 2 trials of OSE-127 could be impacted during the coming months.
For more information:
Click and follow us on Twitter and LinkedIn
https://twitter.com/OSEIMMUNO
https://www.linkedin.com/company/10929673
Contacts
Sylvie Détry Sylvie.detry@ose-immuno.com +33 153 198 757 French Media: FP2COM fportejoie@fp2com.fr +33 607 768 283 | darren@lifescicomms.com +1 646 627 8387 chris@lifesciadvisors.com +41 79 367 6254 |
Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of
These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the
Source:
2020 GlobeNewswire, Inc., source